Cogent Biosciences (COGT) Common Equity (2017 - 2021)
Historic Common Equity for Cogent Biosciences (COGT) over the last 5 years, with Q3 2021 value amounting to $197.2 million.
- Cogent Biosciences' Common Equity rose 98950.12% to $197.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was $197.2 million, marking a year-over-year increase of 98950.12%. This contributed to the annual value of $234.7 million for FY2020, which is 63882.94% up from last year.
- Per Cogent Biosciences' latest filing, its Common Equity stood at $197.2 million for Q3 2021, which was up 98950.12% from $212.8 million recorded in Q2 2021.
- In the past 5 years, Cogent Biosciences' Common Equity registered a high of $234.7 million during Q4 2020, and its lowest value of -$61.3 million during Q1 2018.
- Moreover, its 5-year median value for Common Equity was $44.5 million (2019), whereas its average is $71.1 million.
- In the last 5 years, Cogent Biosciences' Common Equity crashed by 17746.92% in 2020 and then surged by 100599.24% in 2021.
- Quarter analysis of 5 years shows Cogent Biosciences' Common Equity stood at -$48.8 million in 2017, then skyrocketed by 223.31% to $60.2 million in 2018, then plummeted by 47.27% to $31.8 million in 2019, then skyrocketed by 638.83% to $234.7 million in 2020, then dropped by 15.95% to $197.2 million in 2021.
- Its Common Equity stands at $197.2 million for Q3 2021, versus $212.8 million for Q2 2021 and $226.8 million for Q1 2021.